Peptidomimetic Inhibitors for Treatment of Alzheimer's Disease

Back to all technologies
Download as PDF
65232
Alzheimer's disease is a progressive mental deterioration, resulting in loss of memory, confusion and disorientation, and other behavioral problems. Unfortunately, no definitive cure has been developed to treat this disease. Beta-secretase, an important enzyme in the development and onset of Alzheimer's disease, contributes to the formation of amyloid-beta peptides that aggregate in the brain of Alzheimer's patients. Blocking beta-secretase is a potential strategy for the treatment of Alzheimer's disease.

Researchers at Purdue University have developed a series of novel compounds for beta-secretase inhibition that offer improved pharmacological properties. Novel peptidomimetic scaffolds were utilized to replace conventional hydroxyethylamine isosteres and were shown to be good inhibitors of beta-secretase. This series of compounds shows increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability over previously identified inhibitors or beta-secretase.

Advantages:
-Improved pharmacological properties
-Shown to be good inhibitors of beta-secretase

Potential Applications:
-Medical/Health
-Pharmaceutical Industry
Jun 3, 2011
Utility Patent
United States
8,859,590
Oct 14, 2014

Nov 16, 2010
Provisional-Patent
United States
(None)
(None)

Dec 4, 2009
PCT-Patent
WO
(None)
(None)

May 27, 2009
Provisional-Patent
United States
(None)
(None)

Dec 5, 2008
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org